Standards of laboratory practice: cardiac drug monitoring
Population
Patients receiving cardiac drugs for angina, arrhythmias, and congestive heart failure
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
These guidelines warrant TDM implementation for narrow-index cardiac drugs to reduce toxicity; extends prior recommendations with Fab-specific digoxin guidance.
Structured PICO
P
Population
Patients receiving cardiac drugs for angina, arrhythmias, and congestive heart failure
I
Intervention
Therapeutic drug monitoring of cardiac drugs (digoxin, quinidine, procainamide, lidocaine, flecainide)
This document establishes laboratory practice guidelines for the therapeutic monitoring of cardiac drugs, which is crucial due to their narrow therapeutic indices.
Cite This Study
Valdes et al. (1998) conducted a review in Patients requiring cardiac drug monitoring. Therapeutic monitoring of cardiac drugs was evaluated. Guidelines and recommendations are presented for the therapeutic monitoring of cardiac drugs, including digoxin, quinidine, procainamide, lidocaine, and flecainide.